

Management Certification

The undersigned, on behalf of Jaguar Health, Inc. ("the Company"), certifies that the information provided herein is accurate and complete to the best of the Company's knowledge.

1. The Company is current in its disclosure obligations pursuant to the following reporting standard:

SEC Reporting Obligations

- The Company has a reporting obligation under Section 13 or 15(d) of the Exchange Act
- The Company has a reporting obligation under Regulation A (Tier 2)
- The Company has a reporting obligation under Regulation Crowdfunding (CF)
- Other (please describe)

Other Reporting Obligations

- The Company is a U.S. bank, bank holding company, or similar financial institution exempt from SEC registration, has a reporting obligation to a U.S. Bank Regulator and follows OTC Markets' Bank Reporting requirements.
- The Company is exempt from SEC registration and is reporting under the Alternative Reporting Standard

2. Indicate below whether the Company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

3. Indicate below whether the Company is subject to Bankruptcy or reorganization proceedings.

Yes: No:

4. The Company has a Verified Company Profile on OTCMarkets.com.
5. The Company is duly organized and in good standing under the laws of the state or jurisdiction in which the Company is organized or does business.
6. The Company understands and acknowledges its obligations to report company-related actions pursuant to Exchange Act Rule 10b-17 and FINRA Rule 6490.
7. The Company understands and acknowledges its obligations to publicly disclose material information in a timely manner in accordance with applicable U.S. federal securities laws, including but not limited to Section 10(b) of the Exchange Act and Rule 10b-5 thereunder.
8. The Company's transfer agent and its address are listed below. If the Company acts as its own transfer agent, indicate that by listing the Company and its information in the fields provided.¹

Transfer Agent: Equiniti Trust Company, LLC
Address: Attn: EQ Automated Scanning Team
1110 Centre Point Curve, Suite 101, Mendoza Heights, MN 55120

¹ OTCQX, OTCQB, and OTCID companies are required to retain a transfer agent that participates in the Transfer Agent Verified Shares Program. OTCID companies that act as their own transfer agent may submit data directly to OTC Markets.

9. The Company's most recent Annual Report was prepared by:

Below is a list all law firm(s) and attorney(s) (including internal counsel) that acted as the Company's primary legal counsel in preparing its most recent annual report or, if no attorney assisted in preparing the disclosure, the person(s) who prepared the disclosure and their relationship to the Company.

ReedSmith LLP (External Counsel) and Jonathan Wolin, JD, MBA (Internal Counsel)

10. The Company's Officers, Directors and 5% Beneficial Owners are listed below:

The table below provides information regarding all officers and directors of the Company, or any person that performs a similar function, regardless of the number of shares they own. To the best of the Company's knowledge, it includes all individuals or entities beneficially owning 5% or more of any class of the issuer's equity securities. To identify holders of 5% or more, companies may obtain a recent copy of their shareholder list that includes Non-Objecting Beneficial Owners or "NOBOs." SEC Reporting companies may also research their beneficial ownership and insider transaction filings such as on Schedules 13G or 13D or on Forms 3, 4, and 5.

As of (latest practicable date): January 31, 2026

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, ≥ 5% beneficial owner)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
Lisa A. Conte	President & CEO	San Francisco, CA	482	Common Stock	<1%
Dr. Pravin Chaturvedi	Chief Scientific Officer; Chair of Scientific Advisory Board	Andover, MA	201	Common Stock	<1%
Carol Lizak	Chief Financial Officer	San Jose, CA	152	Common Stock	<1%
Steven King	Chief Sustainable Supply, Ethnobotanical Research, and IP Officer	Moss Beach, CA	173	Common Stock	<1%
Jonathan Wolin	Chief of Staff, Chief Compliance Officer, and General Counsel	San Mateo, CA	197	Common Stock	<1%
James Bochnowski	Chairman of the Board (Class I)	Atherton, CA	51	Common Stock	<1%
John Micek III	Director (Class II)	San Francisco, CA	45	Common Stock	<1%
Jonathan B. Siegel (dba JBS Healthcare Ventures LLC)	Director (Class I)	Scarsdale, NY	46	Common Stock	<1%
Anula Jayasuriya	Director (Class III)	Los Altos Hills, CA	45	Common Stock	<1%
Joshua Mailman	Investor	New York, NY	587,320	Common Stock	8%

Any additional material details, including conversion terms of any class of the issuer's equity securities, are below:

See Schedule 13G filed by Mr. Joshua Mailman on 12/17/2025

The Company has Convertible Debt as detailed below:

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (include accrued interest) See 10-Q 09/30/25	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares) See Note (a)	# Shares Converted to Date (See 10-Q 09/30/25)	# of Potential Shares to be Issued Upon Conversion ² Unknown but basis is - see Note (a)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)
1/20/21	\$6,220,812	\$6,983,000	4/01/2026				Streeterville Capital LLC	Note is for – R&D Cholera indication
10/8/20	\$18,000,000	\$1,153,000	Unspecified - Global Amendment				Iliad Research & Trading L.P.	Royalty Agreement
12/22/20	\$12,000,000	\$12,887,000	Unspecified - Global Amendment				Uptown Capital, LLC (f/k/a Irving Park Capital, LLC)	Royalty Agreement
08/04/22	\$12,000,000	\$9,602,000	Unspecified - Global Amendment				Streeterville Capital LLC	Royalty Agreement

Total Outstanding Balance:

Total Shares:

Any additional material details, including footnotes to the table are below :

² The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

Please refer to the 10-Q as of September 30, 2025 filed with the SEC. (a) Listing Rule 5635(d) defines "Minimum Price" as the lower of: (i) the closing price (as reflected on Nasdaq.com); or (ii) the average closing price of the common stock (as reflected on Nasdaq.com) for the five trading days immediately preceding the signing of the binding agreement.

Signature:

Name of Principal Executive Officer or Principal Financial Officer: Lisa A. Conte

Title: President & CEO

Date: February 20, 2026

Signature: /s/ Lisa A. Conte

(Digital Signatures should appear as "/s/ [OFFICER NAME]")